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RAPID COMMUNICATION
A Common Prothrombin Variant (20210 G to A) Increases the Risk of
Myocardial Infarction in Young Women
By F.R Rosendaal, D S Siscovick, S M Schwartz, B M Psaty, T E Raghunathan, and H L Vos
Using specimens from a population-based case control
study among women ages 18 to 44 years in western Wash-
ington, we assessed the relationship between carriership of
a genetic clotting factor II variant (20210 G->A) and myocar-
dial infarction (MI) The factor II variant was previously
shown to be present in 1% to 2% of the population, to in-
crease the levels of factor II, and to be associated with ve-
nous thrombotic disease Personal Interviews and blood
samples were obtained from 79 women with a first myocar-
dial infarction and 381 control women identified through
random-digit telephone dialing. Polymerase chain reaction
(PCR) method was used to determine the factor II genotypes.
The factor II 20210 G to A transition was present more often
in women with MI (5 1%) than among control women (1 6%)
PROTHROMBIN (factoi II) is the piecmsoi of thrombin,the final effector of the clotting cascade that leads to
the foimation of fibun Piothiombm is a key enzyme m the
balance between piocoagulation and anticoagulation because
it potentiates coagulation by positive feedback loops and
also piomotes anticoagulation by the piotem C pathway ' 2
A lecently descnbed genetic vanant of prothiombm is
associated with an mcieased nsk of venous thiombosis ^ The
vanant is located m the 3' untianslated region of the gene (on
chiomosome 11), at position 20210,4 where one nucleotide is
changed (a G to A tiansition) Carneiship of this vanant is
associated with elevated levels oi piothiombm in plasma,
which aie lelated to an mcieased nsk of thiombosis Among
474 patients with a fiist deep-vein thiombosis we found the
20210 G -> A vanant m 6 2%, äs opposed lo 2 3% among
471 healthy contiol subjects Fiom these results we con-
cluded that cainership of the vanant mcieases the nsk of
deep-vein thiombosis 2 3-fold Among patients with herita-
ble thiombophiha, the vanant was found m 18% This high
piopoition is consistent with the hypothesis that the vanant
is a genetic cause of thiombosis In a second sample of 646
unaffected individuals, we found the mutation m 1%, which
led us to the conclusion that the pievalence in The Nethei-
lands is 1% t o 2 % 5
Recently we have shown that another common genetic
abnoimahty, a mutation m clotting factoi V that causes resis-
tance to the anticoagulant effect of activated protem C
(APC),6 mcieases the nsk of myocaidial infarction (MI) m
women ages 18 lo 44 yeais This mutation, factoi V R506Q
01 factoi V Leiden,7 was found m 4 1% of healthy control
women, and 9 5% of women who suffeied an MI at a young
age 8 Caineiship of the factoi V Leiden vanant increased the
nsk of myocaidial infaiction 2 5-fold The nsk of myocaidial
infaiction was high in women who cairied the factoi V
Leiden allele m combination with othei majoi caidiovasculai
nsk factoi s Foi women who canied the factoi V Leiden
and had one 01 moie 'metabohc risk factors' (obesity, hypei
tension, hypeicholesteiolemia, 01 diabetes melhtus), the nsk
was 25-lold mcieased compaied to women with neithei fac-
toi V Leiden noi a metabohc usk lactoi, for women who
smoked and canied the factoi V mutation, the nsk was 32-
fold mcieased lelative lo nonsmokmg noncauieis
The age-adjusted odds ratio for MI was 4 0 (95% confidence
interval 1 1 to 15 1) The relative nsk was high when another
major cardiovascular risk factor was also present, such äs
smoking (odds ratio 43.3,95% confidence interval 6.7 to 281),
and the risk seemed limited to those with other risk factors
These results, in which the effect of major coronary risk
factors is enhanced fourfold to sixfold by the prothrombin
variant, are similar to those previously reported for another
genetic clotting abnormality, factor V Leiden We conclude
that factor II 20210 G to A increases the risk of myocardial
infarction in young women, especially in the women with
other major risk factors for coronary heart disease
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Our pievious analyses have demonstiated thal besides ils
relevance lo pubhc health m young women, oui study also
provides a model for studymg Ihe inteiaction of alherogenic
and thiombogenic nsk factois 8 lo Therefore, we set out to
assess the effect of a newly descnbed prolhiombolic genelic
abnormahly, Ihe piolhombin 20210 G lo A transition This
is a fairly common variant and Ihus of polenlial imporlance
m the etiology of myocaidial infarction
MATERIALS AND METHODS
We conducted a population based case contiol study of myocai-
dial infaiction among women 18 to 44 yeais of age residmg in three
contiguous counües of western Washington state The methods of
the study have been descnbed extensively previously R " Cases weie
women aged 18 to 44, without a pnot history of coionary hearl
disease or ceiebrovasculai disease, who weie diagnosed between
July l, 1991 and Febiuary 28 1995 with a first acute MI Cutena
foi myocaidial infarction weie deflned by evidence of Symptoms,
elevated enzymes, and electrocaidiogiaphic changes 12 Of 165 eligi-
ble patients, 112 paiticipated in an in peison inteiview and 84 were
willing to undeigo venapuncture
Contiols weie identified by landom-digit telephone dialing Eligi
ble weie women aged 18 to 44 yeais hvmg in the same aiea dunng
the time penod of the study without a history of caidiovascular
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disease '3 A household census was completed foi 94 9% of the resi-
dences contacted Of 684 randomly chosen eligible individuals, 525
agreed to a personal interview (response 73%) and of these 391
agreed to venapunctuie
Participating cases and controls were interviewed m person re-
garding histones of diabetes, hypertension, or hypeihpidemia (physi-
cian's diagnosis and drug-treatment), cigaiette smoking, height and
weight, repioductive and contraceptive histones, and demographic
characteostics All questions ehcited infoimation from a time penod
before each case's cardiovascular event, 01 an equivalent date for
controls
We obtamed 30 mL venous blood from the antecubital vein m
EDTA-treated vacutamers, from which the cells were separated by
centnfugation al 2,000g for 10 minutes, the buffy coat was lesus-
pended in phosphate-buffered sahne and frozen at —70°C White
blood cell ahquots weie shipped to Leiden, The Netherlands, where
DNA analysis was performed DNA was extracted liom these sam-
ples essentially äs descnbed by Miller et al l4 Analyzable DNA was
available for 79 women with MI and 381 control subjects (5 women
included in an earher analysis8 were latei classified äs havmg unsta-
ble angma and weie excluded from this analysis) The technician
who performed DNA analyses was blmded äs to whether a specimen
was from a patient or a control subject
The presence of the factor II vanant (20210, G to A replacement)
was first determmed usmg an A-allele-specific polymerase cham
reaction (PCR) accordmg to the method of Glisic and Alavantic I1
The heterozygous AG Status of putative positives was confirmed by
the presence of a ifmdlll restnction site in the relevant PCR-frag-
ment usmg a previously descnbed protocol ^
Smokers were defined äs women who reported smoking currently
and regularly, while all otheis were classified äs nonsmokers A
woman was classified äs diabetic, hypertensive, or hypercholesteiol-
emic if she reported that she had ever been diagnosed by a physician
äs such Additionally, we assessed which women were cuirently
taking prescnption drugs for these conditions We considered obese
any woman with a body mass index (BMI) equal to or exceedmg
27 3 kg/m2 In some analyses the variables for hypertension, hyper-
cholesterolemia, diabetes melhtus, and obesity were giouped to-
gether äs 'metabohc nsk factors '
The association of carnership of the factor II vanant with MI
Table 1 General Characteristics of Patients and Control Subjects
Table 2 Factor II 20210A Among Patients With MI and Controls
and ORs m Relation to Smoking and Metabolie Risk Factors
Age (yr)
Mean
Mediän
Range
Current smokers
Ever diagnosed with
Hypertension
Hypercholesterolemia
Diabetes mellitus
Currently drug treated for
Hypertension
Hypercholesterolemia
Diabetes mellitus
Obese
Patients With MI
(n - 79)
397
41
23 44
59 (747)
27 (342)
33 (41 8)
12 (152)
13 (165)
2 (25)
5 ( 6 3 )
46 (58 2)
Control Women
(n - 381)
377
39
19 44
86 (22 6)
37 (9 7)
60 (157)
11 ( 29 )
10 (2 6)
2 ( 05 )
3 (08)
102 (270)
Factor II Mutation
Smoking
GG
AG
GG
AG
Metabolie nsk
factor
GG
AG
GG
AG
Overall
GG
AG
Other Risk
Factor
No
No
Yes
Yes
No
No
Yes
Yes
Patients
(n - 79)
20
0
55
4
14
0
61
4
75
4
Controls
(n - 381)
291
4
84
2
210
4
162
2
375
6
OR
1
0
93
433
1
0
53
338
1
40
CI95
0 232
52 16 5
67 281
0 245
2 9 9 9
5 5 2 0 9
1 1 15 1
Data were not available for treated hypercholesterolemia m one
control, and body mass mdex m three controls Percentages are given
for available data, in parentheses All data, including diagnosis or
treatment of the conditions mentioned above, refer to dates before
the MI
ORs are adjustedforage, and calculated separately for each stratum
with a dummy variable model, age-adjusted and relative to the refer
ence category (OR 1) Metabolie nsk factors are either obesity or a
physician's diagnosis of diabetes mellitus, hyeprtension, or hypercho
lesterolemia
was exammed by unconditional logistic legression adjusted foi the
matchmg variable age, and expressed with the odds ratio (OR) äs a
measure for relative nsk Effect modification was assessed thiough
stratifled analyses Confidence intervals (95%, CI95) were calculated
by Standard methodology
RESULTS
The 79 women with an acute MI had a mean age of 39 7
(median 41), the control women of 37 7 (median 39 0) All
major nsk factors for coronary disease such äs smoking,
obesity, hypertension, hypercholesteiolemia, and diabetes
were reported more often among cases than among controls
(Table 1) Smoking (75%) and obesity (58%) were particu-
larly prevalent among the patienls
Five percent of women with an MI cartied the factoi II
20210A allele (4 of 79, 5 1%), compared to l 6% of the
control women (6 of 381) (Table 2) All carners of the
mutation were white women whereas none of the 51 non-
white women m the study canied the mutation The OR for
MI (from the age-adjusted logistic model) was 4 0 (CI95 l l
to 15 l, P = 038) These results did not matenally change
when the analyses were restncted to white women (n = 409,
OR = 4 2), premenopausal women (n = 389, OR = 3 7), 01
nonusers of oral contraceptives (n = 414, OR = 63) The
complementary subgroups for these variables included too
few women to allow nsk estimation
The nsk associated with factor II 2021OA was paiticularly
high when other major nsk factors were also present (Table
2) Among nonsmokers or women without metabohc nsk
factors, the risk was not mcieased when women cained the
factor II vanant, but among smokers who cariied the muta-
tion the risk was mcreased 43-fold (CI95 6 7-281) compared
to nonsmokmg women without the factor II vanant, and,
among women with one or more of four metabohc nsk fac-
tors (obesity, hypertension, hypeicholesterolemia, or diabe-
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Table 3 ORs for Cardiovascular Risk Factors and Risk of MI
With and Without the Simultaneous Presence of Clottmg
Factor Abnormality
OR* CI95
Smoking
Without FVL or FII20210A
With FVL or FII20210A
Obesityt
Without FVL or FII20210A
With FVL or FII20210A
Metabolie risk factori
Without FVLor FII20210A
With FVL or FII20210A
86
363
38
205
46
249
47 155
107 123
22-66
47 889
2 4 8 6
83 742
*OR adjusted for age, relative to those with neither the clottmg
abnormality nor the other risk factor
tBMI a 27 3 kg/m2
iObesity or physician s diagnosis of hypertension hypercholester
olemia, or diabetes
tes melhtus) the nsk was mcreased 34-fold (CI95 5 5 to 209)
when they cained the factoi II vanant In contiast, women
with one or more of these metabohc risk factors without the
factor II vanant had a 5 3-fold mcreased risk (CI95 2 9 to
9 9), le, the aheady elevated risk among women with these
risk factoi s was mcreased further by more than sixfold Re-
stnction of this analysis to diug-tieated hypeitension, hyper-
cholesterolemia, or diabetes melhtus (mstead of repoited
physician's diagnosis of these conditions) led to similar re-
sults
These lesults of a stnking synergy with other major car-
diovascular risk factors is similar to what we have previously
descnbed for the association of factor V Leiden (factor V
1691 G to A) and MI among these young women Therefore,
we combmed these two mutations into one vanable repie-
senting either clottmg abnormality, which was piesent in 12
cases (15 2%) and 21 contiols (5 5%) None of the 460
women camed the combination of factoi V Leiden and factoi
II 20210A (located on chromosome l and 11, respectively)
The OR associated with any clottmg abnormality was 3 l,
with a 95% conndence mteival of l 5 to 6 7 (P = 003)
This relative risk indicates a moderate stiength nsk factoi
that mcieases the risk thieefold, however, when the clottmg
abnormality was piesent combmed with other cardiovascular
nsk factors, the relative nsks langed fiom 21 (obesity) to
36 (smoking), compared to women without the other nsk
factor or any clottmg abnormality Table 3 shows the relative
nsks of several majoi deteimmants of coionary disease when
piesent without the clottmg abnoimahty, and when piesent
m combination with the clottmg abnormality The piesence
of eithei prothiombotic mutation (factor V Leiden or factoi
II 20210A) incieased furthei the aheady elevated risk of MI
associated with smoking, obesity, and metabohc nsk factois
by fourfold to sixfold
DISCUSSION
A common vanant in the prothiombin gene, factor II
20210 G to A leplacement, was associated with an oveiall
fouifold incieased risk of MI m young women The vanant
was found m l 6% of healthy young women The relative
nsk became paiticulaily high when other majoi cardiovascu-
lai iisk factois weie also piesent
MI is a lare event in young women Foi MI to occui in
a young individual, several iisk factors need to be piesent
simultaneously, äs is the case foi venous thrombosis 16 20
Theiefoie, young individuals form an excellent group to study
the effect of new nsk factors äs well äs the mteiaction between
nsk factors We have leported pieviously from this study
population that over 95% of cases had at least one of the risk
factois smoking, hypertension, hypeicholesteiolemia, diabe-
tes melhtus, obesity, or factoi V Leiden 8 Smoking and obesity
both were extremely frequent and present in moie than half
of the women with MI Because MI is uncommon m young
women, the absolute individual nsk of disease will remain
low even when the relative iisk is high However, it should
be kept m mind that all majoi diseases aie rare m the young,
and that theiefore even small absolute nsks contribute sigmfi
cantly to overall morbidity and mortahty among the young
The factor V Leiden mutation has a distmct lacial and, to
a lessei extent, geographical distnbution 2122 It is common
in whites and very raie m Asians and Afiicans, among whites
m Europe, theie seems to be a Noith-South giadient, with
prevalences langmg between 2% m Italy to 7% m Sweden
Among 51 nonwhite women in this study, we did not find
any caniers of the factor II mutation Because the overall
prevalence of the factoi II mutation was l 6%, this is obvi-
ously well withm the expected findmg, nevertheless, our data
suggest the possibihty that this vanant, hke the factor V
Leiden mutation, is also present mainly in whites
The fmdings of an association of MI with factoi II 20210
G to A only among young women with other risk factors
are stnkmgly similar to oui pievious leports on factoi V
Leiden in young women 8 Both clottmg abormahties display
a stiong syneigistic effect with other cardiovasculai nsk fac-
tors, in particulai with smoking These two lecently discov-
ered clottmg abnoimahties were piesent m over 5% of the
population, and thus may affect a laige numbei of people
In young women, MI appears to be the lesult of combmed
atherogemc and thiombogenic factors Without a concomit
tant atheiogenic abnoimahty, theie was little effect of the
clottmg abnormality with regaid to the risk of MI The le-
verse seemed tiue, too, äs is shown m Table 3 the vanous
atherogemc iisk factois, such äs obesity, hypeicholestei ol-
emia, hypertension, and diabetes had a modest effect on the
iisk of MI in these women when piesent solely, and this nsk
was greatly enhanced when a clottmg abnoimahty äs factor
V Leiden 01 factoi II 20210A was simultaneously present
Oui results aie based on a small numbei of mutant gene
caniers and therefoie the statistical unceitamty around the
iisk estimates remamed consideiable The confidence mtei-
vals were paiticulaily wide foi the estimates m the mterac-
tion analysis However, because the lesults foi the oveiall
effects of cameiship of factor II 20210 A, äs well äs foi the
mteraction with othei majoi iisk factors for coionary disease,
are similai to those we lepoited pieviously for factoi V
Leiden, we feel confident about oui conclusions of an m
creased iisk and synergism with othei risk factois Although
we found no incieased iisk foi gene caniers who did not
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have another major nsk factor for coronary heait disease,
the confidence mteivals for these estimate weie wide and
did not exclude the possibihty of a mildly mcreased nsk
A further question is whether the association between the
factor II mutation and the nsk of MI is causal and mdeed
brought about by factor II In our previous study m venous
thrombosis we have shown a lelation between the mutation
and factor II levels, which appeared instrumental to the nsk 3
Therefore, even though we could not measme clottmg factor
levels m the current study, it is likely that a piothrombotic
effect of cainership of factoi II 20210 A mcreases the nsk,
since we have shown befoie, among these same women
with MI at a young age, a similar effect of another clottmg
abnormahty (factor V Leiden)8
Although generally there is no reason to assume that nsk
factors in the young quahtatively differ from those in middle-
aged and older adults, they may diffei in their strengths l9 20 23
Therefore, our findings cannot be generahzed to oldei or
male populations It may well be that clottmg factor abnoi-
mahties play a role in the etiology of MI in those populations,
too, but it may be more difficult to discern because with
advancing age both the piesence and seventy of atheroscle-
rosis mcreases, which results in a highei background mci-
dence of MI among those without a particular nsk factor
Addiüonally, laige groups need to be studied to examine
specific mteiactions of atherogenic and prothiombotic nsk
factors m older populations We believe that it will be worth-
while to look foi specific mteractions of nsk factors m those
populations äs well
ACKNOWLEDGMENT
We thank all the women who paiticipated in the study We aic
grateful to the many hospital medical record admmistrators and phy
sicians who assisted m the Identification of patients for this study
Fran Chaid, Kaien Graham, and Carol Handley Dahl expertly ab-
stracted medical tecords, and Judy Kaiser, Marlene Bengeult, Carol
Ostergaid, Denise Horlander, and Barb Twaddell leciuited and mter-
viewed the patients and control subjects Sandy Tronsdal and Jill
Ashman supervised these activities We thank Esthei Vogels who
peiformed the DNA analyses
REFERENCES
1 Jackson CM Physiology and biochemistry of prothrombin,
in Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD (eds)
Haemostasis and Thiombosis Edinburgh, UK, Churchill Living
stone, 1994, p 397
2 Beitina RM, van Tilburg NH, de Fouw NJ, Haverkate F
Thrombin, a Unk between coagulation activation and fibnnolysis
Ann NY Acad Sei 667 239, 1992
3 PooitSR, Rosendaal FR, Reitsma PH, BeitmaRM A common
genetic Variation in the 3'-untranslated legion of the prothiombm
gene is associated with elevated plasma prothiombin levels and an
mcrease m venous thrombosis Blood 88 3698, 1996
4 Degen SJ, Davie EW Nucleotide sequence of the gene tor
human piothrombin Biochemistiy 26 6165, 1987
5 Doggen CJM, Visser T, Bertina RM, Mangel Cats V, Rosen
daal FR Prothrombin 20210 G > A äs a moderate nsk factoi for
myocardial mfarction Thromb Haemost 77 379, 1997 (abstr, suppl)
6 Dahlback B, Cailsson M, Svensson PJ Farmlial thrombophiha
due to a pieviously unrecognised mechamsm chaiactenzed by pooi
anticoagulant lesponse lo activated piotein C Prediction of a cofac-
toi to activated protem C Pioc Natl Acad Sei USA 90 1004, 1993
7 Beitina RM, Koeleman RPC, Kostei T, Rosendaal FR, Dnven
RJ, De Ronde H, Van dei Velden PA, Reitsma PH Mutation in
blood coagulation factoi V associated with resistance to activated
piotein C Natuie 369 64, 1994
8 Rosendaal FR, Siscovick DS, Schwaitz SM, Beveily RK, Psaty
BM, Longstreth WT Jr, Raghunathan TE, Koepsell TD, Reitsma
PH Factoi V Leiden (resistance to activated piotein C) mcreases
the nsk of myocardial infaiction in young women Blood 89 2750,
1997
9 Uhl GS, Fanell PW Myocaidial mfarction m young adults
Risk factoi s and natural histoiy Am Heait J 105 548, 1983
10 Zimmeiman FH, Cameron A, Fishei LD, Ng G Myocaidial
infaiction m young adults Angiogiaphic charactenzation, nsk fac-
tors and prognosis (Coionary Arteiy Suigery Study Registry) J Am
Coll Caidiol 26654, 1995
11 Schwaitz SM, Siscovick DS, Malmow MR, Rosendaal FR,
Beveily RK, Hess DL, Psaty BM, Longstieth WT Ji, Koepsell TD,
Raghunathan TE, Reitsma PH Myocardial mfarclion in young
women m relation to plasma total homocysteme, folate, and a com-
mon vanant m the methylenetetiahydrofolate reductase gene Cucu-
lation 96412, 1997
12 Fried LP, Borham NO, Ennght P, Fuibeig CD, Gaidm JM,
Kronmal RA, Kullei LH, Manoho TA, Mittelmaik MB, Newman
A, O'Leary DH, Psaty BM, Rautahaiju P, Tiacy RP, Weiler PG,
foi the Cardiovascular Health Study Reseaich Group (CHS) The
Caidiovascular Health Study Design and rationale Ann Epidemiol
l 263, 1991
13 Hartge P, Bnnton LA, Roscnthal JF, Cahill JI, Hoovei RN,
Waksberg J Random digit diahng in selecting a population based
contiol group Am J Epidemiol 120 825, 1984
14 Miller SA, Dykes DD, Polesky HF A simple saltmg out
procedute foi extiacting DNA from human nucleated cells Nucleic
Acids Res 16 1215, 1988
15 Ghsic S, Alavantlc D A simple PCR method foi dctection
of defined point mutations Trends Genet 12 391, 1996
16 Sidney S, Petitti DB, Quesenberry CP, Ji , Klatsky AL, Ziel
HK, Wolf S Myocatdial mfarction in useis of low-dose oral contia-
ceptives Obstet Gynccol 88 939, 1996
17 Rosendaal FR Thrombosis m the young epidemiology and
iisk factois, a focus on venous thrombosis Thromb Haemost 78 l,
1997
18 Siscovick DS, Schwartz SM, Rosendaal FR, Psaly BM
Thrombosis in the young Effect of atheroscleiotic nsk factors on the
nsk of myocaidial infaiction associated with piothiombotic factois
Thromb Haemost 78 7, 1997
19 Kamtz MG, Giovannucci SJ, Jones JS, Mott M Myocardial
mfarction m young adults Risk factors and chnical features J Emerg
Med 14 139, 1996
20 McKenna WJ, Chew CY, Oakley CM Myocaidial infaiction
with noimal coionaiy angiogiam Possible mechamsm of smokmg
nsk in coronary aitery disease Br Heait J 43 493, 1980
21 Rees DC, Cox M, Clegg JB Woild distnbution of factoi V
Leiden Lancet 346 1133, 1995
22 Cox MJ, Rees DC, Maitmson JJ, Clegg JB Evidence foi a
smglc ongm of factor V Leiden Br J Haematol 92 1022, 1996
23 Beigstrand R, Vcdm A, Wilhelmsson C, Wallin J, Wedel H,
Wilhelmsen L Myocardial infaiction among men below age 40 Br
Heait J 40 783, 1978
